The Kansas Department of Health and Environment supports these ACIP recommendations. We encourage families with questions to consult with their healthcare provider for guidance based on individual health needs.
-
Individuals aged six months to 64 years: Vaccination based on individual decision-making, with emphasis that vaccination is most favorable for those at increased risk for severe disease according to the CDC list of COVID-19 risk factors.
Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine
-
Children under four years of age receive separate MMR and Varicella vaccines.
-
The combined measles, mumps, rubella, and varicella (MMRV) vaccination continues to be recommended for those children 4 years of age and older.
-
Providers can continue to utilize their current MMRV combination vaccine inventory for those children 4 years of age and older.
Vaccine Ordering Information
Vaccine for Children (VFC) Program
The Kansas Immunization Program (KIP) VFC order window closed Oct. 7, 2025. If enrolled providers need to place COVID-19, MMR, or Varicella vaccine orders, please contact your Regional Immunization Nurse, or email the Vaccine Distribution Team at KDHE.vaccine@ks.gov.
Vaccine for Adults (VFA) Program
COVID-19 vaccine doses for the VFA providers will be available soon. Additional details will be provided when ordering is available.
As a reminder, enrolled VFC and VFA providers are required to follow ACIP recommendations in accordance with federal program guidelines.
Infant Respiratory Syncytial Virus (RSV) prevention season begins on October 1st and continues through March 31st. The Centers for Disease Control and Prevention (CDC) recommends RSV immunization during specific months to maximize protection during peak RSV season, which is usually between December and January.
An RSV monoclonal antibody is recommended for all infants younger than 8 months of age whose mothers did not receive the maternal RSV vaccine (Pfizer’s Abrysvo) during pregnancy. Two long-acting monoclonal antibodies are available for infants: nirsevimab and clesrovimab.
The infant dose should be administered shortly before the start of the RSV season, or within one week of birth for infants born during October through March.
Nirsevimab is also recommended for certain children 8–19 months of age who are at higher risk for severe RSV. Clesrovimab is not recommended for this age group.
The additional nirsevimab dose should be given shortly before the child’s second RSV season and is recommended for:
- Children born prematurely with chronic lung disease
- Children with severe immunocompromise
- Children with severe cystic fibrosis
- American Indian and Alaska Native children
Your recommendation matters. Encourage parents to protect their infants with RSV immunization to reduce the risk of severe illness and hospitalization.
Related links:
- Standing Orders for Administering Nirsevimab RSV Preventive Antibody to Infants
- Standing Orders for Administering Clesrovimab RSV Preventive Antibody (Enflonsia, by Merck) to Infants
- RSV (Respiratory Syncytial Virus) Vaccine and Antibody Resources for Healthcare Providers | Immunize.org
- Ask The Experts About Vaccines: RSV (Respiratory Syncytial Virus) | Immunize.org
For additional information or questions, please contact your Regional Immunization Nurse or the Immunization Nurse On-Call at 877-296-0464 or KDHE.IMMconsultant@ks.gov.
On October 8, 2025, National Foundation for Infectious Diseases (NFID) will host a webinar titled “2025-2026 US Respiratory Season Updates.” Join NFID for a discussion highlighting the importance of immunization to help protect against severe illness during the upcoming respiratory season. The webinar will discuss current US immunization recommendations for influenza, COVID-19, respiratory syncytial virus (RSV), and pneumococcal disease, and strategies to increase immunization rates.
The panel of speakers will include:
- Robert H. Hopkins, Jr., MD, NFID Medical Director
- Matthew M. Zahn, MD, Pediatric Infectious Disease Physician at Rady Children’s Health
- Melody Butler, RN, BSN, CIC, Founding Executive Director and President of Nurses Who Vaccinate and Director of Infection Prevention and Control at Stony Brook Southhampton Hospital
- Brigid K. Groves, PharmD, MS, Vice President of Professional Affairs at the American Pharmacists Association (APhA)
Objectives of the presentation are:
- Discuss current evidence-based recommendations for COVID-19, influenza (flu), respiratory syncytial virus (RSV), and pneumococcal disease immunization in the US.
- Describe the burden of COVID-19, flu, RSV, and pneumococcal disease in the US.
- Implement communication strategies to help increase respiratory disease immunization rates in the US.
Participation in the webinar is free, but pre-registration is required. Continuing education credit is also available.
Kansas participates in the IZ Gateway, which allows participating states to securely share immunization records. Currently, Kansas is connected with:
Arkansas, Colorado, Connecticut, Kentucky, Missouri, Nevada, New Mexico, and Oklahoma.
If you’re not seeing records from another state, the most common reason is an address mismatch. The patient’s address in KSWebIZ must exactly match the address in the other state’s system for the connection to work. Even small differences, such as abbreviations, missing apartment numbers, or spelling variations, can prevent a match.
Once the address matches, records will automatically check and import overnight. You can also manually start this process by selecting “Add History via IZ Gateway Hub” in KSWebIZ after verifying the address.
If records still don’t appear after confirming the address, reach out to the KSWebIZ Helpdesk via email or by phone at 1(877) 296-0464 for assistance.
Tuberculosis Clinical Intensive Oct. 9, 2025 at 7:30 a.m. CST.
Men's Health & HIV: Treating the Whole Person Oct. 9, 2025 at 10:00 a.m. CST
Mini-Residency: HCV Oct. 9, 2025 at 9:00 a.m. CST.
Check out our full trainings list.
|
